Fredun pivots to pet care and physiotherapy, guides 25-30% revenue growth for FY27
New-age consumer businesses grew at 40-50% CAGR and already deliver 55% gross margins, a stark contrast to the 20% from its core pharma contract manufacturing.
— 4 earlier stories on Fredun Pharmaceuticals Ltd. →What's new
- Fredun is pivoting from contract manufacturing to a consumer-focused company, launching Wagga pet platform and Mobilitix physiotherapy brand.
- New-age businesses (pet care, mobility, nutraceuticals, cosmetics) grew at 40-50% CAGR with 45-55% gross margins.
- Management guided for 25-30% topline growth in FY27 and targets 10-12% PAT margins within a few years.
Why this matters
Fredun is making a hard pivot from a low-margin, cyclical contract manufacturing business to higher-margin, direct-to-consumer brands. The scale of the margin differential (20% vs. 55%) justifies the strategic shift, but the company is essentially building a new business alongside its old one. Execution risk is high.
What we're watching
- Adoption metrics for the Wagga and Mobilitix launches in H1 FY27.
- Whether the 25-30% topline growth guide is met without margin dilution.
- The path to ₹100 crore run-rate for the mobility business.
The full read
Fredun Pharmaceuticals is remaking itself. The 19-year-old contract manufacturer, which has never had a year of revenue decline, is now building consumer brands in pet care and physiotherapy. The logic is clear: its legacy pharma business generates 20% gross margins. The new ventures are already hitting 45-55% and growing at a 40-50% CAGR. Management guided for 25-30% topline growth in FY27 and is targeting 10-12% PAT margins in time. The first test comes in weeks, with the soft launch of the Wagga pet platform and the Mobilitix physiotherapy brand. The mobility business did ₹30 crore last year and aims for a ₹100 crore run rate in 2.5 years. The pivot is ambitious. The margin math justifies it. The question is execution.
Questions answered
- What is the core strategic shift Fredun announced?
- Fredun is pivoting from being a contract manufacturer for pharmaceutical companies to becoming a consumer-focused company. It is launching its own brands in pet care, mobility, and other new-age segments.
- How do the economics of the new businesses compare to the old one?
- The new-age businesses are growing at 40-50% CAGR and achieve 45-55% gross margins. This is more than double the 20% gross margin of its vintage pharmaceutical contract manufacturing business.
- What are the specific growth targets for FY27?
- Management guided for 25-30% topline growth in FY27. It also targets achieving 10-12% PAT margins within a few years.
- What are the key product launches mentioned?
- Fredun is soft-launching its Wagga pet platform in mid-June and its Mobilitix physiotherapy brand in July. The mobility business already generated ₹30 crore in revenue in FY26.
- What is the long-term target for the mobility segment?
- Management targets a ₹100 crore run rate for the mobility business within 2 to 2.5 years.
Story so far
All notes on FREDUN →- 10 Jun 2026 · 12:07 PM IST Fredun pivots to pet care and physiotherapy, guides 25-30% revenue growth for FY27
- 15d ago Fredun Pharmaceuticals posts 60% profit jump and declares 2:1 bonus
- 16d ago Fredun Pharmaceuticals lifts profit 60% and declares 2:1 bonus
- 16d ago Fredun Pharma's profit jumps 60%, declares 2:1 bonus
- 16d ago Fredun's profit jumps 60%, board declares 2:1 bonus